The 45th San Antonio Breast Cancer Symposium will host 10,000 clinicians and scientists from all over the world and is the largest and most prestigious scientific gathering on breast cancer research. This international scientific symposium allows for important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer.
VJOncology will be in attendance to help disseminate the latest learnings from the meeting.
🌎 Today marks #WorldCancerDay2023, and visit our website at http://VJOncology.com as we continue to update you on the latest in #oncology with exclusive interviews, insightful sessions, and more!
The 45th San Antonio Breast Cancer Symposium will host 10,000 clinicians and scientists from all over the world and is the largest and most prestigious scientific gathering on breast cancer research. This international scientific symposium allows for important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer.
VJOncology will be in attendance to help disseminate the latest learnings from the meeting.
🌎 Today marks #WorldCancerDay2023, and visit our website at http://VJOncology.com as we continue to update you on the latest in #oncology with exclusive interviews, insightful sessions, and more!
Join us for the next Breast Cancer VJSession where leading breast cancer experts Sara Tolaney, Sarah Sammons, and Paolo Tarantino review the latest updates in breast cancer from SABCS 2022!
Topics cover updates in capivasertib, latest SERD data including elacestrant and camizestrant and other novel ER degraders, strategies post CDK4/6 inhibition, biomarkers for response to antibody-drug conjugates such as HER2-low and TROP-2, as well as updated PFS from DESTINY-Breast03.
SABCS 2022 featured an array of conversations on the field of HER2-low breast cancer, including updates from the results of DESTINY-Breast02, as well as debates as to whether it should be considered a separate entity.